AVM Biotechnology
is a Washington-based biotechnology firm that develops and commercializes regenerative therapeutics for the treatment of cancer... Read moreAVM Biotechnology
is a Washington-based biotechnology firm that develops and commercializes regenerative therapeutics for the treatment of cancer... Read more
2008
PrivateMerger Pending with Ai Technology Group Inc.
News
Jan 12, 2026
Benzinga
AVM Biotechnology: Ai Technology Group and AVM Biotechnology Provide Merger and Operational Update
Oct 10, 2025
GlobeNewswire
Press Release: AVM Biotechnology : AI Technology Group Signs Definitive Agreement to Acquire AVM Biotechnology
Oct 10, 2025
Benzinga
AVM Biotechnology: AI Technology Group Signs Definitive Agreement to Acquire AVM Biotechnology
Sep 11, 2023
Business Wire
Press Release: AVM Biotechnology : AVM Biotechnology Selected by the National Cancer Institute to Present at Bio Investor Forum 2023
Aug 09, 2023
Business Wire
Press Release: AVM Biotechnology : AVM Biotechnology Announces that the National Cancer Institute has selected AVM Biotechnology as a Showcase Company for their 2023-2024 Small Business Innovation Research (SBIR) Investor Initiatives
Aug 02, 2023
StreetInsider
Press Release: AVM Biotechnology : AVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients have been Treated with Immunomodulatory AVM0703 through Expanded Access/Compassionate Use Programs
Aug 25, 2022
Outsourcing-Pharma
AVM Biotechnology: NIH awards SBIR grant to AVM for lymphoma drug research
Jun 14, 2022
Business Wire
Press Release: AVM Biotechnology : AVM Biotechnology Awarded $2 Million National Cancer Institute SBIR Phase II Grant from the National Institutes of Health to Advance AVM0703 in Cancer
Jun 14, 2022
BioSpace
AVM Biotechnology: AVM Biotechnology Awarded $2 Million National Cancer Institute SBIR Phase II Grant from the National Institutes of Health to Advance AVM0703 in Cancer
Jun 01, 2022
Business Wire
Press Release: AVM Biotechnology : AVM Biotechnology to Present Poster Highlighting the Effects of AVM0703 Against Solid Tumors and Blood Cancers at the 2022 ASCO Annual Meeting
AVM Biotechnology Competitors
1
2
3
4
5
6
7
8
9
10